vs

Side-by-side financial comparison of CALIFORNIA WATER SERVICE GROUP (CWT) and Orthofix Medical Inc. (OFIX). Click either name above to swap in a different company.

Orthofix Medical Inc. is the larger business by last-quarter revenue ($219.9M vs $210.7M, roughly 1.0× CALIFORNIA WATER SERVICE GROUP). CALIFORNIA WATER SERVICE GROUP runs the higher net margin — 5.4% vs -1.0%, a 6.5% gap on every dollar of revenue. On growth, Orthofix Medical Inc. posted the faster year-over-year revenue change (2.0% vs -3.3%). Over the past eight quarters, CALIFORNIA WATER SERVICE GROUP's revenue compounded faster (16.6% CAGR vs 8.0%).

California Water Service Group (CWSG) is an American public utility company providing drinking water and wastewater services. It is the third-largest investor-owned publicly traded water utility in the United States, serving roughly two million people through its subsidiary companies in California, Hawaii, New Mexico and Washington. CWSG was formed in 1997 as a new holding company for California Water Service to expand into other states regulated by their own public utilities commissions, and...

Orthofix Medical Inc. is a global medical device firm specializing in orthopedic care. It develops, manufactures and sells spinal implants, trauma care products, bone growth stimulation therapies and regenerative medicine offerings, serving orthopedic surgeons and healthcare providers across North America, Europe and Asia Pacific.

CWT vs OFIX — Head-to-Head

Bigger by revenue
OFIX
OFIX
1.0× larger
OFIX
$219.9M
$210.7M
CWT
Growing faster (revenue YoY)
OFIX
OFIX
+5.3% gap
OFIX
2.0%
-3.3%
CWT
Higher net margin
CWT
CWT
6.5% more per $
CWT
5.4%
-1.0%
OFIX
Faster 2-yr revenue CAGR
CWT
CWT
Annualised
CWT
16.6%
8.0%
OFIX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CWT
CWT
OFIX
OFIX
Revenue
$210.7M
$219.9M
Net Profit
$11.5M
$-2.2M
Gross Margin
71.1%
Operating Margin
12.2%
0.2%
Net Margin
5.4%
-1.0%
Revenue YoY
-3.3%
2.0%
Net Profit YoY
-41.0%
92.4%
EPS (diluted)
$0.19
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CWT
CWT
OFIX
OFIX
Q4 25
$210.7M
$219.9M
Q3 25
$314.1M
$205.6M
Q2 25
$256.2M
$203.1M
Q1 25
$182.7M
$193.6M
Q4 24
$217.8M
$215.7M
Q3 24
$306.2M
$196.6M
Q2 24
$226.7M
$198.6M
Q1 24
$154.9M
$188.6M
Net Profit
CWT
CWT
OFIX
OFIX
Q4 25
$11.5M
$-2.2M
Q3 25
$61.2M
$-22.8M
Q2 25
$42.2M
$-14.1M
Q1 25
$13.3M
$-53.1M
Q4 24
$19.5M
$-29.1M
Q3 24
$60.7M
$-27.4M
Q2 24
$40.6M
$-33.4M
Q1 24
$69.9M
$-36.0M
Gross Margin
CWT
CWT
OFIX
OFIX
Q4 25
71.1%
Q3 25
72.2%
Q2 25
68.7%
Q1 25
62.8%
Q4 24
69.0%
Q3 24
68.7%
Q2 24
67.8%
Q1 24
67.5%
Operating Margin
CWT
CWT
OFIX
OFIX
Q4 25
12.2%
0.2%
Q3 25
22.5%
-8.3%
Q2 25
20.2%
-7.9%
Q1 25
12.2%
-25.2%
Q4 24
14.8%
-5.3%
Q3 24
21.8%
-9.6%
Q2 24
21.2%
-12.5%
Q1 24
50.3%
-15.6%
Net Margin
CWT
CWT
OFIX
OFIX
Q4 25
5.4%
-1.0%
Q3 25
19.5%
-11.1%
Q2 25
16.5%
-6.9%
Q1 25
7.3%
-27.4%
Q4 24
8.9%
-13.5%
Q3 24
19.8%
-13.9%
Q2 24
17.9%
-16.8%
Q1 24
45.1%
-19.1%
EPS (diluted)
CWT
CWT
OFIX
OFIX
Q4 25
$0.19
$-0.05
Q3 25
$1.03
$-0.57
Q2 25
$0.71
$-0.36
Q1 25
$0.22
$-1.35
Q4 24
$0.31
$-0.76
Q3 24
$1.03
$-0.71
Q2 24
$0.70
$-0.88
Q1 24
$1.21
$-0.95

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CWT
CWT
OFIX
OFIX
Cash + ST InvestmentsLiquidity on hand
$51.8M
$82.0M
Total DebtLower is stronger
$1.5B
Stockholders' EquityBook value
$1.7B
$450.0M
Total Assets
$5.7B
$850.6M
Debt / EquityLower = less leverage
0.87×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CWT
CWT
OFIX
OFIX
Q4 25
$51.8M
$82.0M
Q3 25
$76.0M
$62.9M
Q2 25
$50.5M
$65.6M
Q1 25
$44.5M
$58.0M
Q4 24
$50.1M
$83.2M
Q3 24
$59.6M
$30.1M
Q2 24
$37.3M
$26.4M
Q1 24
$42.8M
$27.0M
Total Debt
CWT
CWT
OFIX
OFIX
Q4 25
$1.5B
Q3 25
$1.1B
$157.2M
Q2 25
$1.1B
$157.0M
Q1 25
$1.1B
$156.9M
Q4 24
$1.1B
$157.0M
Q3 24
$118.5M
Q2 24
$118.0M
Q1 24
$118.2M
Stockholders' Equity
CWT
CWT
OFIX
OFIX
Q4 25
$1.7B
$450.0M
Q3 25
$1.7B
$442.5M
Q2 25
$1.7B
$458.3M
Q1 25
$1.6B
$458.3M
Q4 24
$1.6B
$503.1M
Q3 24
$1.6B
$525.9M
Q2 24
$1.5B
$546.0M
Q1 24
$1.5B
$570.3M
Total Assets
CWT
CWT
OFIX
OFIX
Q4 25
$5.7B
$850.6M
Q3 25
$5.5B
$832.6M
Q2 25
$5.4B
$837.2M
Q1 25
$5.3B
$823.1M
Q4 24
$5.2B
$893.3M
Q3 24
$5.0B
$867.9M
Q2 24
$4.9B
$882.0M
Q1 24
$4.8B
$906.0M
Debt / Equity
CWT
CWT
OFIX
OFIX
Q4 25
0.87×
Q3 25
0.65×
0.36×
Q2 25
0.67×
0.34×
Q1 25
0.68×
0.34×
Q4 24
0.67×
0.31×
Q3 24
0.23×
Q2 24
0.22×
Q1 24
0.21×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CWT
CWT
OFIX
OFIX
Operating Cash FlowLast quarter
$47.9M
$27.7M
Free Cash FlowOCF − Capex
$16.8M
FCF MarginFCF / Revenue
7.6%
Capex IntensityCapex / Revenue
4.9%
Cash ConversionOCF / Net Profit
4.17×
TTM Free Cash FlowTrailing 4 quarters
$-1.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CWT
CWT
OFIX
OFIX
Q4 25
$47.9M
$27.7M
Q3 25
$167.3M
$12.4M
Q2 25
$48.9M
$11.6M
Q1 25
$38.4M
$-18.4M
Q4 24
$68.1M
$23.7M
Q3 24
$101.8M
$11.7M
Q2 24
$94.4M
$9.0M
Q1 24
$26.5M
$-18.6M
Free Cash Flow
CWT
CWT
OFIX
OFIX
Q4 25
$16.8M
Q3 25
$2.5M
Q2 25
$4.5M
Q1 25
$-25.1M
Q4 24
$15.2M
Q3 24
$6.3M
Q2 24
$-360.0K
Q1 24
$-29.1M
FCF Margin
CWT
CWT
OFIX
OFIX
Q4 25
7.6%
Q3 25
1.2%
Q2 25
2.2%
Q1 25
-13.0%
Q4 24
7.0%
Q3 24
3.2%
Q2 24
-0.2%
Q1 24
-15.4%
Capex Intensity
CWT
CWT
OFIX
OFIX
Q4 25
4.9%
Q3 25
4.8%
Q2 25
3.5%
Q1 25
3.5%
Q4 24
4.0%
Q3 24
2.7%
Q2 24
4.7%
Q1 24
5.6%
Cash Conversion
CWT
CWT
OFIX
OFIX
Q4 25
4.17×
Q3 25
2.73×
Q2 25
1.16×
Q1 25
2.88×
Q4 24
3.50×
Q3 24
1.68×
Q2 24
2.33×
Q1 24
0.38×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CWT
CWT

Residential$133.2M63%
Business$47.7M23%
Public Authorities$13.4M6%
Industrial$6.9M3%
Non Regulated Services$4.8M2%
Other Non Regulated Service$1.2M1%

OFIX
OFIX

Spinal Implants Biologics And Enabling Technologies$113.6M52%
Bone Growth Therapies$68.3M31%
Other$22.7M10%
IT$5.9M3%
GB$3.5M2%
FR$3.5M2%
DE$2.3M1%

Related Comparisons